Core Insights - Renovaro Inc. has launched Augusta, a Precision Neurology Platform aimed at improving patient stratification, biomarker discovery, and drug validation in neurology, an area that has historically faced challenges in diagnosis and treatment [1][2] Group 1: Platform Features - Augusta integrates multimodal data analytics with proprietary in silico screening, significantly reducing the time required for identifying biomarkers and therapeutics compared to conventional methods [1] - The platform emphasizes interpretability, clinical alignment, and rigorous benchmarking, moving away from black-box approaches [2] - Its modular infrastructure allows for plug-and-play model evaluation, including large language models conditioned with proprietary knowledge graphs, fostering continuous innovation while ensuring clinical robustness [2] Group 2: Validation and Efficacy - The efficacy of Augusta has been demonstrated in Parkinson's Disease through phenoclustering, which identified novel patient subgroups with unique clinical characteristics and biomarkers [3] - In epilepsy, the platform has successfully identified novel lead compounds targeting patient populations with rare genetic mutations [3] Group 3: Future Plans - Renovaro plans to expand its precision neurology efforts into additional neurological disorders and is currently discussing strategic partnerships with academic medical centers and life sciences companies [4] Group 4: Company Overview - Renovaro aims to accelerate precision and personalized medicine for longevity by leveraging AI and biotechnology platforms for early diagnosis, targeted treatments, and drug discovery [5]

LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today agreed on terms for an exclusive collaboration agreement with Amsterdam University Medical Center (“Amsterdam UMC”) to jointly evaluate and develop blood platelet RNA diagnostics. This partnership marks an important step forward in the clinical validation and advancement of a promising new approach to disease det ...

LOS ANGELES, April 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), an AI-driven precision Medicine Company that leverages AI platforms to improve outcomes for cancer and neurologically challenged patients, today announced is expanding our ongoing strategic collaboration with Nebul (www.nebul.com), a leading AI cloud infrastructure company, to advance the early detection of cancer and other diseases. The partnership aims to leverage Renovaro's deep learning and ML programs with Nebul's high-perform ...

Strategic Combination Intended to Drive Advanced AI-Driven Drug Development and Expand Precision Medicine Applications Across Cancer and Neurology LOS ANGELES, April 09, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced it closed its previously announced merger transaction with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and precision ne ...

LOS ANGELES, April 04, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today provided an update regarding its Definitive Agreement with Predictive Oncology Predictive Oncology, Inc. (NASDAQ: POAI) to initiate the previously announced integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States. Reno ...

Company Commits the First Tranche of Financing to Initiate the Integration of AI/ML Platform Technologies, Core Laboratory Capabilities and Business Development Efforts in Europe and the United States Renovaro’s Strategic Acquisition of BioSymetrics Vastly Expands Biomarker and Drug Discovery Opportunities and the Development of Diagnostic Applications in Oncology LOS ANGELES, March 03, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics ...

Strategic Combination Aims to Accelerate Biomarker Identification, Enhance Drug Discovery, and Expand Precision Medicine Applications in Cancer and Beyond LOS ANGELES, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced a definitive agreement to merge with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and biomarker identification co ...

Group 1 - Renovaro Inc. has secured $15 million in additional equity at a price of $1.00 per share, along with a privately placed cash warrant exercisable at $1.50 with a one-year term [1] - The CEO of Renovaro, David Weinstein, stated that the new capital will enable the company to accelerate its focus on revolutionizing healthcare through advanced diagnostics and personalized immunotherapy [2] - Renovaro aims to enhance precision and personalized medicine for longevity by integrating AI and biotechnology platforms for early diagnosis, targeted treatments, and drug discovery [2] Group 2 - Renovaro includes RenovaroBio, which specializes in advanced cell-gene immunotherapy, and RenovaroCube, which utilizes AI for multi-omic diagnostics and drug development [2]

Company Focus and Strategy - Renovaro Inc. has shifted its primary focus to the development of Renovaro Cube technologies following the acquisition of GEDi Cube Intl Ltd. on February 13, 2024[122][123]. - Renovaro Biosciences aims to develop advanced allogeneic cell and gene therapies for long-term cancer remission and treatment of serious infectious diseases, contingent on obtaining necessary funding[123][124]. - The company is actively pursuing partnerships with leading academic cancer centers and pathology centers to enhance multi-omic and multi-modal capacity[157]. - The company intends to commercialize products and test kits for healthcare providers to expedite cancer diagnosis and treatment selection[160]. - The company has streamlined its organization to focus on the development and validation of its AI-driven cancer diagnostics platform[172]. Technology and Product Development - The allogeneic cell therapy platform has completed the pre-IND and IND-enabling phase, focusing on genetically modified dendritic cell therapeutic vaccines for solid tumors[128]. - Renovaro Cube's proprietary AI platform utilizes a multi-omics approach to enhance early cancer detection and diagnosis, targeting biomarkers even in asymptomatic patients[133][134]. - The company is developing multi-cancer early detection (MCED) blood tests to identify abnormal genetic patterns indicative of cancer, potentially improving early detection rates[138]. - Renovaro Cube plans to expand its diagnostic tests and test kits for non-invasive liquid biopsy samples across Europe and the United States[141]. - The AI technology developed by Renovaro Cube aims to enhance the accuracy and sensitivity of early cancer detection, facilitating earlier intervention and improved patient outcomes[142]. - Renovaro Cube's product development strategy includes a focus on recurrence detection, treatment response prediction, and support for clinical trials through patient cohort selection[139]. - The company intends to leverage multi-modal data analysis to provide insights into disease characterization and improve diagnostic accuracy[140]. - The AI platform includes Explainable AI features, ensuring transparency and traceability in its diagnostic processes[165]. - Renovaro Cube's AI technology aims to provide non-invasive alternatives for complex cancer detection procedures, focusing on multi-omics data[27]. Financial Performance and Position - The company incurred a net loss of $7,252,394 and $51,464,429 for the three and six months ended December 31, 2024, respectively[171]. - As of December 31, 2024, the company had cash and cash equivalents of $311,764 and an accumulated deficit of $383,919,510[171]. - Operating expenses for the three months ended December 31, 2024, were $4,546,316, an increase of 6% compared to $4,270,075 in 2023[178]. - General and administrative expenses for the three months ended December 31, 2024, were $4,353,123, reflecting a 20% increase from $3,616,392 in 2023[180]. - Research and development expenses for the three months ended December 31, 2024, decreased by 74% to $161,084 from $620,521 in 2023[182]. - The net loss for the three months ended December 31, 2024, was $7,252,394, representing a 60% increase from $4,529,121 in 2023[186]. - Total assets decreased to $111,340,272 as of December 31, 2024, from $163,129,450 as of June 30, 2024, primarily due to goodwill impairment of $47,614,729[191]. - The company had a working capital deficit of $26,898,493 as of December 31, 2024, compared to $28,312,274 as of June 30, 2024, a decrease of 5%[190]. - Cash used in operating activities for the six months ended December 31, 2024, was $4,576,052, a decrease from $5,923,830 in 2023[192]. - The company recorded other income of $6,420,440 for the six months ended December 31, 2024, compared to other expense of $549,960 in 2023, a change of 1,267%[185]. - The company anticipates needing additional funds for research and development, personnel increases, and technology development in the next twelve months[189]. - As of December 31, 2024, the company had $311,764 in cash, an increase from $220,467 as of June 30, 2024[190]. Future Outlook and Challenges - The company is dependent on additional financing to fund operations, raising substantial doubt about its ability to continue as a going concern[171]. - The company aims to validate its biomarker panels through collaboration with clinical partners in real-world settings[155]. - The company plans to hire additional staff to accelerate the development of its AI platform and infrastructure[158].

Senior Biotechnology and Specialty Healthcare Financial Executive Brings Extensive Experience in Leading Acquisition and Organic Growth Initiatives LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced the appointment of Nathen Fuentes, CPA, as Chief Financial Officer effective January 2, 2025, replacing interim CFO Simon Tarsh. Nathen Fuentes comes to Renovaro as a senior biotechnolog ...